Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS

• Published in: Antibiotics (Basel) Vol. 11; no. 1; p. 54
• Main Authors: Goh, Kelvin Kau-Kiat, Toh, Wilson Ghim-Hon, Hee, Daryl Kim-Hor, Ting, Edwin Zhi-Wei, Chua, Nathalie Grace Sy, Zulkifli, Farah Iffah Binte, Sin, Li-Jiao, Tan, Thuan-Tong, Kwa, Andrea Lay-Hoon, Lim, Tze-Peng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.01.2022; MDPI
• Subjects: Antibiotics; Assaying; Aztreonam; Bacteria; Blood plasma; Calibration; Cations; Cefepime; Ceftazidime; Drug dosages; Drug therapy; Feasibility studies; Fosfomycin; Gram-negative bacteria; Guidelines; Infections; LCMS/MS; Levofloxacin; Mass spectrometry; Mass spectroscopy; Meropenem; Patients; Piperacillin; Plasma; Quality control; Scientific imaging; Tazobactam; TDM; Tigecycline; validation; LCMS/MS; TDM; plasma; antibiotics; fosfomycin; validation
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics11010054

Fosfomycin-based combination therapy has emerged as an attractive option in our armamentarium due to its synergistic activity against carbapenem-resistant Gram-negative bacteria (CRGNB). The ability to simultaneously measure fosfomycin and other antibiotic drug levels will support in vitro and clinical investigations to develop rational antibiotic combination dosing regimens against CRGNB infections. We developed an analytical assay to measure fosfomycin with nine important antibiotics in human plasma and cation-adjusted Mueller–Hinton II broth (CAMHB). We employed a liquid-chromatography tandem mass spectrometry method and validated the method based on accuracy, precision, matrix effect, limit-of-detection, limit-of-quantification, specificity, carryover, and short-term and long-term stability on U.S. Food & Drug Administration (FDA) guidelines. Assay feasibility was assessed in a pilot clinical study in four patients on antibiotic combination therapy. Simultaneous quantification of fosfomycin, levofloxacin, meropenem, doripenem, aztreonam, piperacillin/tazobactam, ceftolozane/tazobactam, ceftazidime/avibactam, cefepime, and tigecycline in plasma and CAMHB were achieved within 4.5 min. Precision, accuracy, specificity, and carryover were within FDA guidelines. Fosfomycin combined with any of the nine antibiotics were stable in plasma and CAMHB up to 4 weeks at −80 °C. The assay identified and quantified the respective antibiotics administered in the four subjects. Our assay can be a valuable tool for in vitro and clinical applications.